NBIX
Neurocrine Biosciences, Inc.
Set alert
146.10 USD -0.28 -0.19%
145.22 Day range 149.25
123.10 52-week range 185.50
- YTD
- +3.01%
- 1 year
- +5.84%
- Open
- 147.13
- Prev close
- 146.38
- Mkt cap
- 14.85B
- Vol
- 1.32M
- Avg vol
- 1.29M
- EPS
- 6.82
- P/E
- 21.42
- Div yield
- 0.00%
More statistics
- Low
- 145.22
- High
- 149.25
- Forward P/E
- 12.20
- Beta
- 0.40
- Short ratio
- 4.41
- Inst. own
- 104.21%
- Dividend
- 0.00
- Ex-div date
- Dec 28, 1995
- Earnings
- Nov 2, 2026
- 50-d avg
- 146.77
- 200-d avg
- 147.33
- 1y target
- 206.22
Financial health
Altman Z-Score
6.88 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A4 / 5 overall
- DCF 5
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 3
- P/E 2
- P/B 2
Valuation
P/E 29.5×
FY 2016 5y median 51.5× FY 2025
P/S 4.9×
FY 2016 5y median 6.8× FY 2025
P/B 4.3×
FY 2016 5y median 5.8× FY 2025
P/FCF 18.8×
FY 2016 5y median 34.6× FY 2025
EV/EBITDA 20.7×
FY 2016 5y median 31.4× FY 2025
EV/Sales 4.8×
FY 2016 5y median 6.9× FY 2025
FCF Yield 5.3%
FY 2016 5y median 2.9% FY 2025
Profitability
Gross Margin 98.2%
FY 2016 5y median 98.4% FY 2025
Operating Margin 21.6%
FY 2016 5y median 16.7% FY 2025
Net Margin 16.7%
FY 2016 5y median 13.2% FY 2025
ROE 14.7%
FY 2016 5y median 11.2% FY 2025
ROIC 10.8%
FY 2016 5y median 9.0% FY 2025
ROA 10.3%
FY 2016 5y median 7.7% FY 2025
Growth (YoY)
Revenue 21.4%
FY 2016 FY 2025
Operating Income 8.5%
FY 2016 FY 2025
EPS (diluted) 41.9%
FY 2016 FY 2025
Free Cash Flow 34.4%
FY 2016 FY 2025
Financial Health
Current Ratio 3.4×
FY 2016 5y median 3.4× FY 2025
Quick Ratio 3.3×
FY 2016 5y median 3.3× FY 2025
Debt / Equity 0.1×
FY 2016 5y median 0.2× FY 2025
Net Debt / EBITDA -0.4×
FY 2016 5y median 0.3× FY 2025
Interest Coverage 0.0×
FY 2016 5y median 4.5× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31